Cohort 2 IN-COL patients had lower circulating MAIT cells at
baseline compared with IN-NAE.
Prior to therapy, patients who subsequently developed IN-COL had
significantly lower circulating MAIT cells at baseline (0.0% of T
cells) than those in the IN-NAE group (1.4% p<0.02; Figure
4a-b). This was also the case while on treatment, as IN-COL at the time
of colitis (0.0%) had lower counts than those in the IN-NAE group at
week 7-10 of TX (0.7%; see Supplementary Table I). Patients with active
UC had lower proportions of circulating MAIT cells (0.3%) compared with
healthy volunteers (1.0%; p<0.02; Figure 4a). Absence of
non-specific background staining for CD161 and CCR6 was demonstrated
using isotype control antibodies (see Supplementary Figure 2bi).
There were no differences in the proportion of circulating
CD25high CD127low Treg or
CD45RA- memory Treg between those with IN-COL and
IN-NAE, nor those with UC or healthy volunteers (see Supplementary Table
I).